2021/10/04

マンスリーおすすめ論文(2021/10)

とあるルート（・・・・・・）からきた 今月のおすすめです👩‍⚕️
CNS
PubMed
https://pubmed.ncbi.nlm.nih.gov/28885118/
Stereotactic radiosurgery for Spetzler-Martin Grade IV and V arteriovenous malformations: an international multicenter study - PubMed
OBJECTIVE Due to the complexity of Spetzler-Martin (SM) Grade IV-V arteriovenous malformations (AVMs), the management of these lesions remains controversial. The aims of this multicenter, retrospective cohort study were to evaluate the outcomes after single-session stereotactic radiosurgery (SRS) fo &

PubMed
https://pubmed.ncbi.nlm.nih.gov/32562682/
Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial - PubMed
National Institute of Neurological Disorders and Stroke for the randomisation phase and Vital Projects Fund for the follow-up phase.

子宮頸がん
PubMed
https://pubmed.ncbi.nlm.nih.gov/34506246/
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial - PubMed
IG-IMRT results in reduced toxicity with no difference in disease outcomes.
😎これは最近取り上げましたPARCER trial🇮🇳ね
https://radoncol.blogspot.com/2021/09/parcer-trial.html
子宮頸がん術後放射線療法---PARCER trial
直腸がん
PubMed
https://pubmed.ncbi.nlm.nih.gov/34196693/
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial - PubMed
ClinicalTrials.gov Identifier: NCT02921256.

TNT関連ではRAPIDO trial🇳🇱とPRODIGE 23 trial🇫🇷について取り上げたことも😎
https://radoncol.blogspot.com/2021/08/total-neoadjuvant-therapy.html
Total neoadjuvant therapyとはなんだろう❓❓
前立腺がん
PubMed
https://pubmed.ncbi.nlm.nih.gov/34161051/
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer - PubMed
Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrial &

肺がん
PubMed
https://pubmed.ncbi.nlm.nih.gov/34455431/
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial - PubMed
ClinicalTrials.gov Identifier: NCT01965223.
これはnoteで取り上げられていた方がいましてね😎 貼っておきます。
note（ノート）
https://note.com/nijuoti/n/n14c88d4bc9ff
お勉強198:SBRT　１Fr vs. ４Fr｜nijuoti｜note
https://jamanetwork.com/journals/jamaoncology/article-abstract/2783660 辺縁処方 28 Gy/1Frと48Gy/4Frを比べるという（BED10はほぼ同等） PIIのランダム化比較試験
その他
PubMed
https://pubmed.ncbi.nlm.nih.gov/34543682/
Increasing demand on human capital and resource utilization in radiotherapy: The past decade - PubMed
This work demonstrates the increase in resource utilization due to the introduction of advanced technologies and changes in radiotherapy techniques over the past decade. Human resource utilization is the predominant factor and should be considered with increasing patient volume for operational plann &
contributed by